Akebia Therapeutics (NASDAQ:AKBA) will release its earnings data after the market closes on Monday, March 18th. Analysts expect Akebia Therapeutics to post earnings of ($0.27) per share for the quarter.
Shares of AKBA opened at $8.17 on Friday. The firm has a market cap of $457.94 million, a PE ratio of -4.62 and a beta of 1.46. Akebia Therapeutics has a 12-month low of $5.20 and a 12-month high of $13.05.
A number of brokerages have recently issued reports on AKBA. Zacks Investment Research lowered shares of Akebia Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, March 1st. BidaskClub raised shares of Akebia Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Thursday, February 7th. Finally, ValuEngine lowered shares of Akebia Therapeutics from a “hold” rating to a “sell” rating in a research note on Tuesday, January 22nd. Two investment analysts have rated the stock with a sell rating, two have issued a hold rating and four have assigned a buy rating to the company. The stock currently has a consensus rating of “Hold” and a consensus target price of $15.04.
ILLEGAL ACTIVITY WARNING: This piece was originally published by Zolmax and is the property of of Zolmax. If you are viewing this piece on another publication, it was illegally copied and republished in violation of international copyright law. The legal version of this piece can be viewed at https://zolmax.com/investing/akebia-therapeutics-akba-scheduled-to-post-earnings-on-monday/2966297.html.
Akebia Therapeutics Company Profile
Akebia Therapeutics, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for patients with renal disease through hypoxia-inducible factor (HIF) biology. Its lead product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease in dialysis and non-dialysis patients.
Further Reading: How to calculate the intrinsic value of a stock
Receive News & Ratings for Akebia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akebia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.